AU2008289462B2 - Compositions of humanized notch fusion proteins and methods of treatment - Google Patents

Compositions of humanized notch fusion proteins and methods of treatment Download PDF

Info

Publication number
AU2008289462B2
AU2008289462B2 AU2008289462A AU2008289462A AU2008289462B2 AU 2008289462 B2 AU2008289462 B2 AU 2008289462B2 AU 2008289462 A AU2008289462 A AU 2008289462A AU 2008289462 A AU2008289462 A AU 2008289462A AU 2008289462 B2 AU2008289462 B2 AU 2008289462B2
Authority
AU
Australia
Prior art keywords
human
notch
decoy
notchl
notch4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008289462A
Other languages
English (en)
Other versions
AU2008289462A1 (en
Inventor
Jan Kitajewski
Carrie Shawber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Original Assignee
Columbia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University filed Critical Columbia University
Publication of AU2008289462A1 publication Critical patent/AU2008289462A1/en
Application granted granted Critical
Publication of AU2008289462B2 publication Critical patent/AU2008289462B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
AU2008289462A 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment Ceased AU2008289462B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96605207P 2007-08-23 2007-08-23
US60/966,052 2007-08-23
PCT/US2008/010045 WO2009025867A2 (en) 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment

Publications (2)

Publication Number Publication Date
AU2008289462A1 AU2008289462A1 (en) 2009-02-26
AU2008289462B2 true AU2008289462B2 (en) 2014-01-23

Family

ID=40378882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008289462A Ceased AU2008289462B2 (en) 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment

Country Status (15)

Country Link
US (2) US9127085B2 (enExample)
EP (1) EP2193143B1 (enExample)
JP (2) JP2010536855A (enExample)
KR (1) KR20100076947A (enExample)
CN (1) CN101883786A (enExample)
AU (1) AU2008289462B2 (enExample)
BR (1) BRPI0815291A2 (enExample)
CA (1) CA2697262A1 (enExample)
IL (2) IL204111A (enExample)
MX (1) MX2010002053A (enExample)
NZ (3) NZ600171A (enExample)
RU (1) RU2532830C2 (enExample)
SG (1) SG183763A1 (enExample)
WO (1) WO2009025867A2 (enExample)
ZA (1) ZA201001427B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009103637A1 (en) * 2008-02-22 2009-08-27 Vrije Universiteit Brussel Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
KR20110074846A (ko) * 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
EP2493497A4 (en) * 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
DK2924052T3 (da) * 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
WO2014151950A1 (en) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver
US20160030513A1 (en) * 2013-03-15 2016-02-04 The Trustees Of Columbia University In The City Of New York Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver
WO2016167306A1 (ja) * 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトＮｏｔｃｈ４抗体
US11026996B2 (en) 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
US12065479B2 (en) 2017-11-16 2024-08-20 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
CN109467598B (zh) * 2018-11-28 2021-11-09 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
US20230174633A1 (en) * 2020-03-30 2023-06-08 Memorial Sloan Kettering Cancer Center Methods and compositions for modulating lipid storage in adipose tissue
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN114062682A (zh) * 2021-11-10 2022-02-18 厦门大学附属心血管病医院 Notch3作为检测靶标的应用
CN115584341A (zh) * 2022-11-07 2023-01-10 浙江大学 一种鱼成肌细胞分化培养基及人造鱼肉组织方法
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261477A1 (en) * 2002-09-10 2005-11-24 Champion Brian R Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060030694A1 (en) * 2004-04-29 2006-02-09 Jan Kitajewski Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20070104746A1 (en) * 2005-07-29 2007-05-10 Seishiro Fujii Methods and compositions for reducing skin damage

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
GB9623236D0 (en) * 1996-11-07 1997-01-08 Imperial College Notch
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
EP1492816A2 (en) 2002-04-05 2005-01-05 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
EP1525221A1 (en) * 2002-08-03 2005-04-27 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
KR20110074846A (ko) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261477A1 (en) * 2002-09-10 2005-11-24 Champion Brian R Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060030694A1 (en) * 2004-04-29 2006-02-09 Jan Kitajewski Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20070104746A1 (en) * 2005-07-29 2007-05-10 Seishiro Fujii Methods and compositions for reducing skin damage

Also Published As

Publication number Publication date
JP2010536855A (ja) 2010-12-02
RU2010110812A (ru) 2011-09-27
MX2010002053A (es) 2010-07-28
KR20100076947A (ko) 2010-07-06
EP2193143B1 (en) 2016-06-08
EP2193143A2 (en) 2010-06-09
US20110008342A1 (en) 2011-01-13
NZ583649A (en) 2012-06-29
CA2697262A1 (en) 2009-02-26
US9127085B2 (en) 2015-09-08
RU2532830C2 (ru) 2014-11-10
EP2193143A4 (en) 2012-01-25
BRPI0815291A2 (pt) 2015-02-03
NZ600171A (en) 2014-01-31
JP2016040245A (ja) 2016-03-24
SG183763A1 (en) 2012-09-27
WO2009025867A3 (en) 2009-12-30
US20160115217A1 (en) 2016-04-28
NZ618129A (en) 2015-05-29
CN101883786A (zh) 2010-11-10
WO2009025867A2 (en) 2009-02-26
IL220723A0 (en) 2012-08-30
AU2008289462A1 (en) 2009-02-26
IL204111A (en) 2015-08-31
ZA201001427B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
US9127085B2 (en) Compositions of humanized notch fusion proteins and methods of treatment
JP2010536855A5 (enExample)
US8993725B2 (en) Notch-based fusion proteins and uses thereof
US9475855B2 (en) Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
He et al. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis
JP6605467B2 (ja) Ｖｅｇｆ−ｃおよびｃｃｂｅ１の治療的使用
JP2009515520A (ja) 肝細胞成長因子イントロン融合蛋白
AU2009200385A1 (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
KR20010042364A (ko) 성숙 ＦＬＩＮＴ(ｍＦＬＩＮＴ) 폴리펩타이드 또는 ＴＮＦ수용체인 ＯＰＧ3의 치료학적 용도
US7947278B2 (en) Methods of modulating angiogenesis
JP2004506595A (ja) 血管形成及び心臓血管新生の促進又は阻害
AU2019408055A1 (en) Chimeric antigen receptors (CARs) and their use in medicine
HK1151983B (en) Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired